ScholarLens Back to search
2012•MD Conference ExpressRequires access

Single-Agent Doxorubicin versus Doxorubicin Plus Ifosfamide in Advanced Soft Tissue Sarcoma

T. Rizzo, W. van der Graaf

Open publisher page 0 citations

Abstract

Patients with locally advanced unresectable or metastatic soft tissue sarcoma have poor outcomes. Palliative chemotherapy is standard treatment for these patients, but it generally results in considerable toxicity. Previous studies have compared single-agent doxorubicin with doxorubicin plus ifosfamide, but the optimal doses remain unclear. This article discusses the European Organisation for Research and Treatment of Cancer 62012 Phase 3 study [NCT00061984] in patients with advanced soft tissue sarcoma.

About this research paper

What this paper is about

Patients with locally advanced unresectable or metastatic soft tissue sarcoma have poor outcomes. Palliative chemotherapy is standard treatment for these patients, but it generally results in considerable toxicity. Previous studies have compared single-agent doxorubicin with doxorubicin plus ifosfamide, but the optimal doses remain unclear. This article discusses the European Organisation for Research and Treatment of Cancer 62012 Phase 3 study [NCT00061984] in patients with advanced soft tissue sarcoma.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Patients with locally advanced unresectable or metastatic soft tissue sarcoma have poor outcomes. Palliative chemotherapy is standard treatment for these patients, but it generally results in considerable toxicity. Previous studies have compared single-agent doxorubicin with doxorubicin plus ifosfamide, but the optimal doses remain unclear. This article discusses the European Organisation for Research and Treatment of Cancer 62012 Phase 3 study [NCT00061984] in patients with advanced soft tissue sarcoma.

Key concepts: Ifosfamide, Doxorubicin, Soft tissue sarcoma, Sarcoma, Medicine, Chemotherapy, Soft tissue, Oncology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Single-Agent Doxorubicin versus Doxorubicin Plus Ifosfamide in Advanced Soft Tissue Sarcoma — Research Paper | ScholarLens